<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04321993</url>
  </required_header>
  <id_info>
    <org_study_id>SAIL-004</org_study_id>
    <nct_id>NCT04321993</nct_id>
  </id_info>
  <brief_title>Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients</brief_title>
  <official_title>Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lisa Barrett</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nova Scotia Health Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalhousie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigational medications adjunct to clinical standard of care treatment will be assessed
      to evaluate safety and effectiveness as an anti-COVID-19 treatment. All hospitalized persons
      with moderate to severe COVID-19 disease that meet eligibility criteria will be offered
      participation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical status of subject at day 15 (on a 7 point ordinal scale).</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>Not hospitalized, no limitations on activities
Not hospitalized, limitation on activities;
Hospitalized, not requiring supplemental oxygen;
Hospitalized, requiring supplemental oxygen;
Hospitalized, on non-invasive ventilation or high flow oxygen devices;
Hospitalized, on invasive mechanical ventilation or ECMO;
Death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Status on an ordinal scale assessed daily while hospitalized and on days 15 and 29 and 180.</measure>
    <time_frame>Up to 180 days</time_frame>
    <description>Not hospitalized, no limitations on activities
Not hospitalized, limitation on activities;
Hospitalized, not requiring supplemental oxygen;
Hospitalized, requiring supplemental oxygen;
Hospitalized, on non-invasive ventilation or high flow oxygen devices;
Hospitalized, on invasive mechanical ventilation or ECMO;
Death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of time to clinical improvement</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>Time to clinical improvement is defined as the time to normalization of respiratory rate, fever, and oxygen saturation, and alleviation of cough within 72 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with normal pulmonary function and normal O2 saturation on days 11, 15 and 29</measure>
    <time_frame>Up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that developed Acute Respiratory Distress Syndrome (ARDS) after treatment</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of time to clinical progression</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>Time to clinical progression, defined as the time to death, mechanical ventilation, or ICU admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause of death (if applicable)</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) score, daily while hospitalized and on days 15 and 29. (Initial, highest, deltas and mean)</measure>
    <time_frame>Up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of time to normalization of fever</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>Fever normalization as defined by: Temperature &lt; 36.6 °C armpit, &lt; 37.2 °C oral, or &lt; 37.8 °C rectal sustained for minimum 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of time to normalization of oxygen saturation</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>Oxygen normalization as defined by: peripheral capillary oxygen saturation (Sp02) &gt; 94% sustained minimum 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of supplemental oxygen (if applicable)</measure>
    <time_frame>Up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation (if applicable)</measure>
    <time_frame>Up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>Up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 180 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Global and SARS-CoV-2-specific immune responses before, during and after intervention and in standard of care treatment arm</measure>
    <time_frame>Up to 180 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent of subjects with SARS-CoV-2 detectable in blood at days 3, 5, 8, 11, 15, 29 and 180.</measure>
    <time_frame>Up to 180 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quantitative SARS-CoV-2 viral load in blood at days 3, 5, 8, and 11, 15, 29, and 180.</measure>
    <time_frame>Up to 180 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Baricitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Clinical standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib (janus kinase inhibitor)</intervention_name>
    <description>Baricitinib 2 mg po daily for 10 days</description>
    <arm_group_label>Baricitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  Moderate to severe COVID-19 associated disease as defined by the WHO

          -  Hospitalized patient

          -  Willing and able to provide written informed consent prior to performing study
             procedures

          -  Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other
             commercial or public health assay

          -  Illness of any duration, and at least one of the following: Radiographic infiltrates
             by imaging (chest x-ray, CT scan, etc.), or Clinical assessment (evidence of
             rales/crackles on exam) AND SpO2 ≤ 94% on room air, or Require mechanical ventilation
             and/or supplemental oxygen.

          -  Febrile defined as temperature ≥ 36.6 °C armpit, ≥ 37.2 °C oral, or ≥ 37.8 °C rectal
             documented within 48 hours of consent

        Exclusion Criteria:

          -  Participation in any other clinical trial of an experimental treatment for COVID-19

          -  Concurrent treatment with other agents with actual or possible direct acting antiviral
             activity against SARS-CoV-2 is prohibited &lt; 24 hours prior to study medication
             initiation

          -  SOFA &gt;10

          -  Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 5 X upper limit
             of normal (ULN)

          -  Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR &lt; 30)

          -  Pregnant women or women who are breastfeeding

          -  Immunocompromised patients taking medication upon screening

          -  Consideration by the investigator, for any reason, that the subject is an unsuitable
             candidate to receive study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Barbara Goodall</last_name>
    <phone>(902) 292-0132</phone>
    <email>barbara.goodall@nshealth.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Barrett</last_name>
    <phone>(902) 473-6446</phone>
    <email>lisa.barrett@nshealth.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nova Scotia Health Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Barrett, MD</last_name>
      <email>lisa.barrett@nshealth.ca</email>
    </contact>
    <contact_backup>
      <last_name>Barbara Goodall</last_name>
      <email>barbara.goodall@nshealth.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nova Scotia Health Authority</investigator_affiliation>
    <investigator_full_name>Lisa Barrett</investigator_full_name>
    <investigator_title>Clinician Scientist</investigator_title>
  </responsible_party>
  <keyword>COVID</keyword>
  <keyword>coronavirus</keyword>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Janus Kinase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

